Published in Br J Haematol on March 01, 1990
In vitro differentiation of endothelial cells from AC133-positive progenitor cells. Blood (2000) 3.57
Randomized comparison of interferon-alpha with busulfan and hydroxyurea in chronic myelogenous leukemia. The German CML Study Group. Blood (1994) 2.78
[Diagnosis and therapy of primary stomach lymphoma. Consensus of the Surgical Working Group for Oncology, the Working Group for Medical Oncology and the Working Group for Radiologic Oncology]. Dtsch Med Wochenschr (1997) 1.93
Possible transfer of Pneumocystis carinii between immunodeficient patients. Lancet (1990) 1.88
Derivation of a new hematopoietic cell line with endothelial features from a patient with transformed myeloproliferative syndrome: a case report. Cancer (2000) 1.60
Vascular endothelial growth factor, a possible paracrine growth factor in human acute myeloid leukemia. Blood (1997) 1.59
TNF-induced cardiomyopathy. Lancet (1990) 1.47
Pharmacokinetics of undiluted or diluted high-dose etoposide with or without busulfan administered to patients with hematologic malignancies. J Clin Oncol (1994) 1.40
[Adult-onset Still's disease]. Med Klin (Munich) (1995) 1.39
Demonstration of i(17q) in metaphase and interphase of malignant hematopoietic cells by fluorescence in situ hybridization. Cancer Genet Cytogenet (1994) 1.39
[New indications for thalidomide?]. Dtsch Med Wochenschr (2001) 1.38
Polymorphisms of glutathione S-transferases (GST) and thymidylate synthase (TS)--novel predictors for response and survival in gastric cancer patients. Br J Cancer (2006) 1.23
Randomized comparison of busulfan and hydroxyurea in chronic myelogenous leukemia: prolongation of survival by hydroxyurea. The German CML Study Group. Blood (1993) 1.16
Pretreatment serum levels of matrix metalloproteinase-9 and vascular endothelial growth factor in non-small-cell lung cancer. Ann Oncol (2002) 1.14
Dynamics of BCR-ABL mRNA expression in first-line therapy of chronic myelogenous leukemia patients with imatinib or interferon alpha/ara-C. Leukemia (2003) 1.11
Gemcitabine, vinorelbine and cisplatin combination chemotherapy in advanced non-small cell lung cancer: a phase II trial. Eur J Cancer (2002) 1.11
Cologne high-dose sequential chemotherapy in relapsed and refractory Hodgkin lymphoma: results of a large multicenter study of the German Hodgkin Lymphoma Study Group (GHSG). Ann Oncol (2005) 1.10
Chromosomal abnormalities in human neoplasia. Annu Rev Med (1970) 1.10
Expression of FLT4 and its ligand VEGF-C in acute myeloid leukemia. Leukemia (1997) 1.03
Time-intensified dexamethasone/cisplatin/cytarabine: an effective salvage therapy with low toxicity in patients with relapsed and refractory Hodgkin's disease. Ann Oncol (2002) 1.01
Melanoma-associated expression of vascular endothelial growth factor and its receptors FLT-1 and KDR. J Cancer Res Clin Oncol (1999) 1.00
[Chemotherapy of malignant bone tumors]. Chirurg (1977) 0.95
Randomized phase III study of gemcitabine and vinorelbine versus gemcitabine, vinorelbine, and cisplatin in the treatment of advanced non-small-cell lung cancer: from the German and Swiss Lung Cancer Study Group. J Clin Oncol (2004) 0.95
18FDG-PET following treatment as valid predictor for disease-free survival in Hodgkin's lymphoma. Ann Oncol (2001) 0.95
Letter: Chromosome abnormalities in angioimmunoblastic lymphadenopathy. Lancet (1976) 0.93
Neutrophilic leukemia accompanied by hemorrhagic diathesis: report of two cases. Blut (1987) 0.93
Effect of eledoisin on tear volume and tear flow in humans as assessed by fluorophotometry. Graefes Arch Clin Exp Ophthalmol (1991) 0.92
Multiparameter analyses of normal and malignant human plasma cells: CD38++, CD56+, CD54+, cIg+ is the common phenotype of myeloma cells. Ann Hematol (1992) 0.91
Continuing medical education in Europe: towards a harmonised system. Eur J Cancer (2010) 0.91
Karyotype in multiple myeloma and plasma cell leukaemia. Eur J Cancer (1993) 0.91
Weekly high-dose 5-fluorouracil and folinic acid as salvage treatment in advanced gastric cancer. Ann Oncol (1994) 0.91
The use of dose-intensified chemotherapy in the treatment of metastatic nonseminomatous testicular germ cell tumors. German Testicular Cancer Study Group. Semin Oncol (1998) 0.90
Whole-body positron emission tomography (PET) for diagnosis of residual mass in patients with lymphoma. Ann Oncol (1997) 0.90
Phase II trial of vinorelbine and trastuzumab in patients with HER2-positive metastatic breast cancer. A prospective, open label, non-controlled, multicenter phase II trial (to investigate efficacy and safety of this combination chemotherapy). Invest New Drugs (2008) 0.89
Stromal abnormalities in neoplastic bone marrow diseases. Ann Hematol (1996) 0.89
Long-term survival of patients with acute myeloid leukemia: a third follow-up of the Fourth International Workshop on Chromosomes in Leukemia. Cancer (1997) 0.89
Clonal growth of Hodgkin cells. Nature (1975) 0.89
Chronic myeloid leukemia in the elderly: long-term results from randomized trials with interferon alpha. Leukemia (2003) 0.89
Genetic abnormalities in chronic lymphocytic leukemia and their clinical and prognostic implications. Cancer Genet Cytogenet (1997) 0.88
A new conditioning regimen involving total marrow irradiation, busulfan and cyclophosphamide followed by autologous PBSCT in patients with advanced multiple myeloma. Bone Marrow Transplant (2003) 0.87
Detection of t(11;18)(q21;q21) by interphase fluorescence in situ hybridization using API2 and MLT specific probes. Blood (2000) 0.87
Genetic abnormalities in marginal zone B-cell lymphoma. Hematol Oncol (2000) 0.87
Translocations t(11;18)(q21;q21) and t(14;18)(q32;q21) are the main chromosomal abnormalities involving MLT/MALT1 in MALT lymphomas. Leukemia (2003) 0.87
Antiangiogenic treatment with endostatin inhibits progression of AML in vivo. Leukemia (2005) 0.87
Hand-foot syndrome associated with short infusions of combination chemotherapy with gemcitabine and vinorelbine. Ann Oncol (2001) 0.86
Correlations between karyotype and cytologic findings in multiple myeloma. Leukemia (1995) 0.86
Comparative analysis of the impact of risk profile and of drug therapy on survival in CML using Sokal's index and a new score. German chronic myeloid leukaemia (CML)-Study Group. Br J Haematol (1997) 0.86
Gender aspects in chronic myeloid leukemia: long-term results from randomized studies. Leukemia (2005) 0.86
Ph1-positive megakaryoblastic leukemia. Cancer (1975) 0.85
GCSF gene is expressed but not rearranged in a patient with isochromosome 17q positive acute nonlymphocytic leukemia. Cancer Genet Cytogenet (1993) 0.85
Cytogenetic studies in malignant fibrous histiocytoma. Cancer Genet Cytogenet (1997) 0.85
A phase II combination trial with recombinant human tumor necrosis factor and gamma interferon in patients with colorectal cancer. Klin Wochenschr (1991) 0.85
A randomized trial with mitomycin-C/ifosfamide versus mitomycin-C/vindesine versus cisplatin/etoposide in advanced non-small-cell lung cancer. Am J Clin Oncol (1991) 0.84
Fatal pulmonary hemorrhage in patients with acute leukemia and fulminant pneumonia caused by Stenotrophomonas maltophilia. Ann Hematol (1997) 0.83
Treatment of acute myeloid leukemia and myelodysplastic syndrome by low dose cytosine arabinoside. Haematol Blood Transfus (1985) 0.83
The significance of trisomy 8 in de novo acute myeloid leukaemia: the accompanying chromosome aberrations determine the prognosis. German AML Cooperative Study Group. Br J Haematol (1997) 0.83
Sister chromatid exchange and chromosome abnormalities in uremic patients. Cancer Genet Cytogenet (1988) 0.82
Results of chromosome studies and their relation to morphology, course, and prognosis in 120 patients with de novo myelodysplastic syndrome. Cancer Genet Cytogenet (1990) 0.82
Lactic acidosis and hypoglycemia in a patient with high-grade non-Hodgkin's lymphoma and elevated circulating TNF-alpha. Ann Hematol (1996) 0.82
Docetaxel combined with irinotecan or 5-fluorouracil in patients with advanced oesophago-gastric cancer: a randomised phase II study. Br J Cancer (2012) 0.82
Clinical and prognostic significance of the Philadelphia chromosome in adult patients with acute lymphoblastic leukemia. Ann Hematol (1992) 0.81
Role of angiogenesis inhibitors in acute myeloid leukemia. Cancer J (2002) 0.81
Pharmacokinetics and pharmacodynamics of the new podophyllotoxin derivative NK 611. A study by the AIO groups PHASE-I and APOH. Cancer Chemother Pharmacol (1996) 0.81
Enhanced platelet aggregation with TRAP-6 and collagen in platelet aggregometry in patients with venous thromboembolism. Thromb Res (2002) 0.80
The ESMO programme of certification and training for medical oncology. Ann Oncol (1998) 0.80
Pharmacokinetics and metabolism of iodo-doxorubicin and doxorubicin in humans. Eur J Clin Pharmacol (1990) 0.80
Prognostic significance of chromosome analysis in de novo acute myeloid leukemia (AML). Blut (1988) 0.80
Cytogenetics in multiple myeloma and plasma cell leukemia: simultaneous cytogenetic and cytologic studies in 51 patients. Ann Hematol (1992) 0.80
Indirect radiation leukemogenesis in DBA/2 mice: increased expression of B2 repeats in FDC-P1 cells transformed by intracisternal A-particle transposition. Ann Hematol (1998) 0.80
Intermittent 2-hour-infusion of cladribine as first-line therapy or in first relapse of progressive advanced low-grade and mantle cell lymphomas. Leuk Lymphoma (1999) 0.80
Non-overt disseminated intravascular coagulation in patients during treatment with antithymocyte globulin for unrelated allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant (2003) 0.80
Treatment of mantle-cell lymphomas with intermittent two-hour infusion of cladribine as first-line therapy or in first relapse. Ann Oncol (1999) 0.80
Early results of combined modality therapy of patients with Ewing's sarcoma. Recent Results Cancer Res (1982) 0.79
Double minute chromosomes: a frequent marker in leukemic patients with a previous history of malignant disease? Cancer Genet Cytogenet (1982) 0.79
Chromosomal abnormality inv(3)(q21q26) associated with multilineage hematopoietic progenitor cells in hematopoietic malignancies. Cancer Genet Cytogenet (1997) 0.79
The pharmacokinetics and toxicity of two application schedules with high-dose VP-16 in patients receiving an allogeneic bone marrow transplantation. Ann Oncol (1996) 0.79
Analysis of the P53, RB/D13S25, and P16 tumor suppressor genes in marginal zone B-cell lymphoma: An interphase fluorescence in situ hybridization study. Cancer Genet Cytogenet (2000) 0.79
Pharmacokinetics of high-dose VP-16: 6-hour infusion versus 34-hour infusion. Bone Marrow Transplant (1994) 0.78
Chromosome studies in acute leukemias developing in patients with multiple myeloma. Cancer Res (1975) 0.78
No evidence of significant activity of the multidrug resistance gene product in primary human breast cancer. Ann Oncol (1998) 0.78
Chromosome findings in effusions from patients with Hodgkin's disease. Int J Cancer (1978) 0.78
Translocation (9;11)(p21;q23) in a child with acute monoblastic leukemia following 2 1/2 years after successful chemotherapy for neuroblastoma. J Clin Oncol (1986) 0.78
Hematopoietic growth factors and the treatment of tumor-associated anemias. Ann Hematol (1994) 0.78
A phase II study of sequential recombinant interleukin-2 followed by dacarbazine in metastatic melanoma. Eur J Cancer (1992) 0.78
A clinical trial of edrecolomab, interleukin-2 and GM-CSF in patients with advanced colorectal cancer. Oncol Rep (2001) 0.78
Cytogenetic studies in 69 patients with myelodysplastic syndromes (MDS). Eur J Haematol (1987) 0.78
Comparison of chromosome analysis and BCL-1 rearrangement in a series of patients with multiple myeloma. Br J Haematol (1992) 0.78
[Cisplatin, vindesine and VP 16-213 in the treatment of inoperable non-small cell bronchial carcinoma. A clinical phase II study]. Onkologie (1984) 0.78
An ovarian thecoma with a single numerical aberration: +12. Cancer Genet Cytogenet (1993) 0.78
Time benefit in the assessment of recurrences following fractionated radiotherapy in an experimental tumour system using positron-emission tomography with 18F-fluorodeoxyglucose. Int J Radiat Biol (2004) 0.78
Phase II study of carboplatin in untreated, inoperable non-small-cell lung cancer. Cancer Chemother Pharmacol (1990) 0.78
Gemcitabine and vinorelbine as first-line chemotherapy for advanced non-small cell lung cancer: a phase II trial. Eur J Cancer (2001) 0.78